U.S. Food Stock News

NYSE:PRI
NYSE:PRIInsurance

Is Primerica (PRI) Pricing Reflect Its Franchise Model Strengths And Recent Share Performance

If you are wondering whether Primerica's current share price still offers value, the recent mix of returns gives you a useful starting point to question what the market is really pricing in. The stock last closed at US$248.46, with returns of a 1% decline over 7 days, a 1% decline over 30 days, a 4% decline year to date, while still showing gains of 60.3% over 3 years and 87.2% over 5 years. Recent news coverage has focused on Primerica's role as a US insurance provider and distributor of...
NasdaqGS:MANH
NasdaqGS:MANHSoftware

Is Manhattan Associates (MANH) Still Attractive After Recent Share Price Weakness?

Wondering if Manhattan Associates at around US$138 per share still offers value, or if most of the opportunity has already been priced in. The stock is down about 3.6% over the past week, 1.6% over the past month, and 17.4% year to date, with a 20.8% decline over the last year and a 19.5% gain over five years. These moves can change how investors think about both risk and opportunity. Recent coverage has focused on Manhattan Associates as a key player in supply chain and warehouse management...
NYSE:APH
NYSE:APHElectronic

Has The Recent Pullback In Amphenol (APH) Opened A New Opportunity For Investors

Investors may be wondering if Amphenol at around US$127.81 still offers good value after its strong run, or if the price now reflects too much optimism. The stock has pulled back recently, with a 5.0% decline over the last week, a 12.9% decline over the last month, and an 8.5% decline year to date, even after a 90.6% return over the past year and a very large 3-year gain of more than 3 times. These moves come as investors continue to reassess large, established tech hardware names, with...
NYSE:CDRE
NYSE:CDREAerospace & Defense

Why Cadre Holdings (CDRE) Is Down 8.5% After Mixed Q4 Results And Aggressive 2026 M&A Guidance

In March 2026, Cadre Holdings, Inc. reported fourth-quarter 2025 sales of US$167.22 million, down from US$175.98 million a year earlier, alongside lower quarterly earnings per share, even as full-year 2025 revenue and net income rose versus 2024 and the company issued 2026 net sales guidance of US$736 million to US$758 million. Management highlighted a growing backlog and strong balance sheet while signaling an active M&A pipeline in public safety and nuclear markets, indicating a push to...
NasdaqGS:FLEX
NasdaqGS:FLEXElectronic

Assessing Flex (FLEX) Valuation After New NVIDIA AI Power Hardware Launch

Why Flex’s New AI Power Hardware Matters for Investors Flex (FLEX) is drawing attention after unveiling its 800 VDC Power Rack with NVIDIA and new reference designs for the NVIDIA Omniverse DSX Blueprint, both focused on high density AI and data center power. These launches tie directly into Flex’s AI Infrastructure Platform and come alongside its broader work with AMD and expanded manufacturing capacity in North America and Mexico, giving investors fresh information about its role in AI...
NYSE:CWK
NYSE:CWKReal Estate

Cushman And Wakefield Taps Victoria Lake To Shape APAC And EMEA Finance

Cushman & Wakefield (NYSE:CWK) has appointed Victoria Lake as Chief Financial Officer for its APAC & EMEA regions. Lake joins the company from Accenture, bringing experience in corporate development, M&A and strategic finance. The appointment reflects a focus on the company’s international business outside the US. Cushman & Wakefield, a global commercial real estate services firm, generates revenue from services such as leasing, property management, capital markets and advisory work...
NYSE:DELL
NYSE:DELLTech

Dell’s New NVIDIA AI Platforms Test Enterprise Demand And Margins

Dell Technologies (NYSE:DELL) has launched new AI infrastructure and data platforms in partnership with NVIDIA, including the Dell AI Data Platform and next generation AI Factory offerings. The company introduced what it describes as the first OEM desktops powered by NVIDIA GB300 Grace Blackwell and new Pro Max systems built around the GB300 Grace Blackwell Ultra Superchip. Dell also announced expanded AI agent capabilities, fresh sector deployments, and new collaborations, including work...
NYSE:WSM
NYSE:WSMSpecialty Retail

Williams Sonoma (WSM) Margin Decline Questions Premium P E Narrative After FY 2026 Results

Williams-Sonoma (WSM) has wrapped up FY 2026 with fourth quarter revenue of US$2.4b and basic EPS of US$3.09, set against a trailing twelve month revenue base of US$7.8b and EPS of US$8.96. Over recent quarters the company has seen revenue move from US$2.5b in Q4 FY 2025 to US$2.4b in Q4 FY 2026, while quarterly EPS shifted from US$3.12 to US$3.09. This is prompting investors to focus on how modest growth expectations line up with a slightly lower trailing net margin and what that may...
NasdaqGS:ALAB
NasdaqGS:ALABSemiconductor

Assessing Astera Labs (ALAB) Valuation After Amazon Warrant Deal And Growing AI Supplier Confidence

Amazon warrant deal and GTC spotlight put Astera Labs in focus Astera Labs (ALAB) has moved into the spotlight after a US$6.5b warrant agreement with Amazon and a scheduled presentation at NVIDIA’s GTC AI Conference 2026 in San Jose on March 17. See our latest analysis for Astera Labs. Despite the excitement around the Amazon warrant deal and GTC appearance, Astera Labs’ 90 day share price return of 13.39% and year to date share price return of 29.64% point to fading short term momentum,...
NYSE:FG
NYSE:FGInsurance

A Look At F&G Annuities & Life (FG) Valuation After New US$100 Million Buyback Approval

F&G Annuities & Life (FG) has drawn fresh attention after its Board approved a new stock repurchase program of up to US$100 million through March 31, 2029, expanding existing buyback capacity. See our latest analysis for F&G Annuities & Life. The announcement comes after a period where momentum in FG has cooled. The 7 day share price return was 12.29%, following a 30 day share price decline of 16.77% and a 1 year total shareholder return of 42.81% in decline. If you are reassessing your...
NasdaqGS:HOLX
NasdaqGS:HOLXMedical Equipment

Is It Time To Reconsider Hologic (HOLX) After A 30% DCF Valuation Gap?

If you are wondering whether Hologic at around US$75.15 is priced for opportunity or already reflects much of the story, the valuation picture is the place to start. The stock has been relatively steady in the short term, with a 0.3% decline over the last 7 days and a 0.1% gain over 30 days, while the 1 year return of 22.3% contrasts with modest 3 year and 5 year returns of 4.4% and 4.4%. Recent coverage has focused on Hologic as a key medical technology player, with attention on how its...
NYSE:HRL
NYSE:HRLFood

Hormel Foods (HRL) Valuation Check After Limited Edition SPAM Bachan’s Collaboration

SPAM’s New Collaboration Puts Hormel Foods in the Spotlight Hormel Foods (HRL) is drawing fresh attention after its SPAM brand partnered with Bachan's to launch a limited edition SPAM Japanese Barbecue Sauce Flavored product, inspired by fan driven recipes and social media trends. See our latest analysis for Hormel Foods. Despite the buzz around SPAM’s latest launch, Hormel Foods’ 1 month share price return of 4.5% and 1 year total shareholder return of 20.3% decline suggest momentum has been...
NYSE:QBTS
NYSE:QBTSSoftware

D-Wave Quantum Expands Gate-Model Reach As QCaaS Bookings Gain Traction

D-Wave Quantum (NYSE:QBTS) has agreed to acquire Quantum Circuits, Inc., expanding into gate-model quantum computing alongside its existing quantum annealing focus. The company has also secured a significant enterprise Quantum-Compute-as-a-Service (QCaaS) agreement, signaling growing commercial use of its quantum offerings. These developments arrive alongside a surge in bookings, pointing to increasing customer engagement with D-Wave's technology stack. D-Wave Quantum operates as a quantum...
NasdaqGM:CRML
NasdaqGM:CRMLMetals and Mining

Assessing Critical Metals (CRML) Valuation As Greenland Rare Earth Plans Accelerate And Capital Options Expand

Shelf registration signals push to fund Greenland rare earth plans Critical Metals (CRML) has filed a US$25.2 million shelf registration covering 2,744,062 ordinary shares. This provides the company with flexibility to access equity markets as it advances its Greenland focused rare earth portfolio. See our latest analysis for Critical Metals. The share price has been volatile around the recent news flow, with a 7 day share price return of 10.10% decline and a 90 day share price return of...
NYSEAM:TMP
NYSEAM:TMPBanks

Will Tompkins Financial’s New Bank President-Elect Reshape Its Long-Term Strategy Story (TMP)?

Tompkins Financial Corp. recently announced that Phillip M. Quintana has been appointed President-Elect of Tompkins Community Bank, succeeding long-serving president John McKenna upon his planned retirement in July 2026. This leadership transition brings more than 27 years of banking leadership experience into a central role at Tompkins Community Bank, potentially influencing its commercial, retail, and credit operations. With this leadership succession plan now public, we’ll assess how...
NasdaqGS:MCHP
NasdaqGS:MCHPSemiconductor

Mythic’s Neuromorphic Design Win Might Change The Case For Investing In Microchip Technology (MCHP)

In early March 2026, Mythic announced it had selected Microchip Technology’s Silicon Storage Technology memBrain neuromorphic hardware IP, using SuperFlash embedded non-volatile memory bitcells to power its next-generation analog processing units for edge and data center AI acceleration. This design win highlights Microchip’s role as an enabling IP provider for power-efficient AI hardware, potentially expanding its reach beyond traditional microcontrollers into compute-in-memory...
NYSE:SLG
NYSE:SLGOffice REITs

SL Green Refocuses Portfolio As 7 Dey Sale Meets Leasing Momentum

SL Green Realty (NYSE:SLG) has agreed to sell the residential and retail components of 7 Dey Street. The company reports that One Madison Avenue is now fully leased. SL Green also highlights significant Manhattan leasing activity so far this year. For investors watching NYSE:SLG, these updates come at a time when the stock trades at $38.37 and has seen very different returns over various time frames, with a 1.5% gain over the past week alongside a 31.8% decline over the past year and a...
NasdaqGS:KMB
NasdaqGS:KMBHousehold Products

Kimberly-Clark (KMB) Valuation Check As Portfolio Reshaping And Kenvue Deal Follow Strong Sales And Dividend Focus

Kimberly-Clark (KMB) has been in focus after divesting its U.S. private label diaper business, reporting strong organic sales and adjusted operating profit, and preparing for the pending Kenvue acquisition while maintaining its long dividend track record. See our latest analysis for Kimberly-Clark. Despite the recent business reshaping and leadership changes, including the appointment of a new Chief Information and Global Business Services Officer, Kimberly-Clark’s 30-day share price return...
NYSE:BE
NYSE:BEElectrical

Bloom Energy (BE) Valuation Check As Brookfield’s US$5b Data Center Partnership Targets Rising AI Power Demand

Bloom Energy (BE) is back in focus after Brookfield Asset Management agreed to invest up to US$5 billion to deploy the company’s fuel cell systems in data centers serving growing AI power needs. See our latest analysis for Bloom Energy. The Brookfield deal follows a powerful run in Bloom Energy’s shares, with a 90 day share price return of 95.21% and a year to date share price return of 58.66%. The 1 year and 3 year total shareholder returns are very large, signalling strong momentum despite...
NasdaqCM:ONCY
NasdaqCM:ONCYBiotechs

Is It Time To Reconsider Oncolytics Biotech (ONCY) After A Huge DCF Valuation Gap?

Wondering if Oncolytics Biotech at around US$0.96 is attractively priced or a value trap? This article walks through the key signals to help you frame that question clearly. The stock has seen mixed returns, with a 54.8% gain over the past year contrasted by a 4.9% decline over 7 days, a 9.4% decline over 30 days, and a 2.4% decline year to date, plus a 21.3% decline over 3 years and a 76.6% decline over 5 years. Recent attention on the company has focused on its position in the biotech...
NYSE:APTV
NYSE:APTVAuto Components

Aptiv’s Ethics Streak Meets Versigent Spin Off And Debt Rework

Aptiv (NYSE:APTV) has been named one of the 2026 World’s Most Ethical Companies by Ethisphere. This is the 14th consecutive year the company has received this recognition. The award highlights Aptiv’s focus on ethics, integrity, and governance in its global operations. Aptiv, a global technology company serving the automotive and mobility sectors, operates at the intersection of vehicle electronics, safety systems, and software defined features. As the industry moves toward more connected...
NasdaqGS:FFIV
NasdaqGS:FFIVCommunications

Is It Time To Reconsider F5 (FFIV) After Its Recent Mixed Share Price Performance?

Wondering if F5 at around US$282.20 is offering good value or asking too much? This breakdown is designed to help you frame that question clearly before you make any moves. The stock has seen mixed recent returns, with a 2.5% decline over the last 7 days, a 3.0% gain over the past month, 10.0% year to date, and 4.4% over the last year. The 3 year and 5 year returns stand at 100.6% and 42.7% respectively. Recent coverage around F5 has focused on how investors are weighing long term...
NYSE:ADC
NYSE:ADCRetail REITs

How Agree Realty’s Higher Monthly Dividend and Institutional Demand Will Impact Agree Realty (ADC) Investors

Agree Realty Corporation recently declared a monthly cash dividend of US$0.262 per common share and US$0.08854 per Series A preferred depositary share, with the payouts scheduled in April 2026 to shareholders of record in March, marking an annualized increase in the common dividend. This dividend increase, alongside very large growth in institutional holdings and reaffirmed analyst confidence, highlights how income-focused investors view Agree Realty’s retail-focused portfolio as an...
NYSE:JNJ
NYSE:JNJPharmaceuticals

Does FDA Approval Of Oral Psoriasis Drug ICOTYDE Reshape The Bull Case For Johnson & Johnson (JNJ)?

On 18 March 2026, Johnson & Johnson received U.S. FDA approval for ICOTYDE (icotrokinra), the first targeted oral IL-23 receptor antagonist for moderate-to-severe plaque psoriasis in adults and eligible adolescents, supported by Phase 3 data showing strong skin clearance rates and a safety profile close to placebo at 16 weeks. Beyond psoriasis, ICOTYDE is being investigated in psoriatic arthritis, ulcerative colitis and Crohn’s disease, positioning it as a potential oral backbone across...